JIA
MCID: JVN010
MIFTS: 67

Juvenile Rheumatoid Arthritis (JIA)

Categories: Bone diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Juvenile Rheumatoid Arthritis

MalaCards integrated aliases for Juvenile Rheumatoid Arthritis:

Name: Juvenile Rheumatoid Arthritis 12 74 52 25 58 6 15 71 32
Juvenile Idiopathic Arthritis 12 52 25 58 36 15 17
Juvenile Arthritis 52 42 71 32
Juvenile Chronic Arthritis 52 25 58
Monarticular Juvenile Rheumatoid Arthritis 12 71
Systemic Juvenile Rheumatoid Arthritis 12 25
Pauciarticular Juvenile Arthritis 12 32
Juvenile Chronic Polyarthritis 12 71
Arthritis, Juvenile Rheumatoid 52 25
Acute Polyarticular Juvenile Rheumatoid Arthritis 71
Pauciarticular Onset Juvenile Chronic Arthritis 12
Pauciarticular Juvenile Rheumatoid Arthritis 71
Rheumatoid Arthritis, Systemic Juvenile 71
Acute Juvenile Rheumatoid Arthritis 12
Arthritis Juvenile Rheumatoid 54
Juvenile Ra 25
Jia 25
Jra 25

Characteristics:

Orphanet epidemiological data:

58
juvenile idiopathic arthritis
Prevalence: 1-9/100000 (Europe),1-9/100000 (France); Age of onset: Childhood;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:676
KEGG 36 H01672
MESH via Orphanet 44 D001171
ICD10 via Orphanet 33 M08.0 M08.1 M08.2 more
UMLS via Orphanet 72 C0553662 C1444838 C3495559
Orphanet 58 ORPHA92
UMLS 71 C0157916 C0157917 C0157918 more

Summaries for Juvenile Rheumatoid Arthritis

Genetics Home Reference : 25 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints. Researchers have described seven types of juvenile idiopathic arthritis. The types are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history. Systemic juvenile idiopathic arthritis causes inflammation in one or more joints. A high daily fever that lasts at least 2 weeks either precedes or accompanies the arthritis. Individuals with systemic arthritis may also have a skin rash or enlargement of the lymph nodes (lymphadenopathy), liver (hepatomegaly), or spleen (splenomegaly). Oligoarticular juvenile idiopathic arthritis (also known as oligoarthritis) is marked by the occurrence of arthritis in four or fewer joints in the first 6 months of the disease. It is divided into two subtypes depending on the course of disease. If the arthritis is confined to four or fewer joints after 6 months, then the condition is classified as persistent oligoarthritis. If more than four joints are affected after 6 months, this condition is classified as extended oligoarthritis. Individuals with oligoarthritis are at increased risk of developing inflammation of the eye (uveitis). Rheumatoid factor positive polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor positive) causes inflammation in five or more joints within the first 6 months of the disease. Individuals with this condition also have a positive blood test for proteins called rheumatoid factors. This type of arthritis closely resembles rheumatoid arthritis as seen in adults. Rheumatoid factor negative polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor negative) is also characterized by arthritis in five or more joints within the first 6 months of the disease. Individuals with this type, however, test negative for rheumatoid factor in the blood. Psoriatic juvenile idiopathic arthritis involves arthritis that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a condition characterized by patches of red, irritated skin that are often covered by flaky white scales. Some affected individuals develop psoriasis before arthritis while others first develop arthritis. Other features of psoriatic arthritis include abnormalities of the fingers and nails or eye problems. Enthesitis-related juvenile idiopathic arthritis is characterized by tenderness where the bone meets a tendon, ligament, or other connective tissue. The most commonly affected places are the hips, knees, and feet. This tenderness, known as enthesitis, accompanies the joint inflammation of arthritis. Enthesitis-related arthritis may also involve inflammation in parts of the body other than the joints. The last type of juvenile idiopathic arthritis is called undifferentiated arthritis. This classification is given to affected individuals who do not fit into any of the above types or who fulfill the criteria for more than one type of juvenile idiopathic arthritis.

MalaCards based summary : Juvenile Rheumatoid Arthritis, also known as juvenile idiopathic arthritis, is related to rheumatoid factor-negative juvenile idiopathic arthritis and rheumatoid arthritis, systemic juvenile, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Juvenile Rheumatoid Arthritis is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Naproxen and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include joint, bone and t cells, and related phenotypes are arthritis and fever

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

NIH Rare Diseases : 52 Juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. When the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. Some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. Like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors . To be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. Diagnosis of the condition may be based on blood tests, X-rays , and ruling out other similar conditions. Treatment options may include medications and physical therapy .

MedlinePlus : 42 Juvenile arthritis (JA) is arthritis that happens in children. It causes joint swelling, pain, stiffness, and loss of motion. It can affect any joint, but is more common in the knees, hands, and feet. In some cases it can affect internal organs as well. The most common type of JA that children get is juvenile idiopathic arthritis. There are several other forms of arthritis affecting children. One early sign of JA may be limping in the morning. Symptoms can come and go. Some children have just one or two flare-ups. Others have symptoms that never go away. JA can cause growth problems and eye inflammation in some children. No one knows exactly what causes JA. Most types are autoimmune disorders. This means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. JA can be hard to diagnose. Your health care provider may do a physical exam, lab tests, and x-rays. A team of providers usually treats JA. Medicines and physical therapy can help maintain movement and reduce swelling and pain. They may also help prevent and treat complications. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

KEGG : 36 Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. Clinically, it is defined as arthritis of unknown origin that starts before the age of 16, and persists for at least 6 weeks. Next to a certain genetic predisposition, environmental factors play a role leading to a chronic inflammatory response. JIA is not a single disorder but consists of a heterogeneous group of auto-immune inflammatory diseases. It has variable rates in course and activity of disease. Based on 6 months of clinical symptoms and global prognostic factors, the following clinical subtypes of JIA are recognized: systemic JIA, oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic JIA, enthesitis- related arthritis, and undifferentiated arthritis. Systemic JIA, also known as Still's disease, is a subtype with strong systemic clinical symptoms. Patients with systemic JIA have, in addition to arthritis, prominent symptoms of systemic inflammation such as spiking fever, rash, pericarditis, peritonitis, lymphadenopathy and organomegaly. A severe and often life-threatening complication occurring in 10-30% of patients with systemic JIA is macrophage activation syndrome. Polymorphisms in the IL6 and in the MIF gene have been found to be associated with susceptibility to the disorder. Based on the known relevance of IL6 in JIA pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA.

Wikipedia : 74 Juvenile idiopathic arthritis (JIA), is the most common form of arthritis in children and adolescents.... more...

Related Diseases for Juvenile Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Juvenile Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1056)
# Related Disease Score Top Affiliating Genes
1 rheumatoid factor-negative juvenile idiopathic arthritis 34.8 SLC11A1 IL2RB IL2RA HLA-DRB1
2 rheumatoid arthritis, systemic juvenile 34.2 IL6 IL2RB IL1R1 HLA-DRB1
3 oligoarticular juvenile idiopathic arthritis 34.2 TNF IL2RB IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
4 systemic onset juvenile idiopathic arthritis 33.7 TNF IL1RN
5 adult-onset still's disease 32.6 TNF IL6 IL1RN IL1R1 HLA-DRB1 CRP
6 iridocyclitis 31.9 TNFRSF1B TNF IL6 DEK CRP
7 uveitis 31.6 TNFRSF1B TNF LTA IL6 IL2RA IL1R1
8 enthesopathy 31.6 TNFRSF1B TNF CRP
9 amyloidosis 31.6 TNF IL6 IL1RN CRP
10 iritis 31.5 TNFRSF1B TNF IL6 CRP
11 synovitis 31.5 TNF IL6 IL1RN CRP
12 ankylosis 31.5 TNFRSF1B TNF CRP BGLAP
13 pericarditis 31.4 TNF IL6 IL1RN CRP
14 vasculitis 31.4 TNFRSF1B TNF S100A9 IL6 CRP
15 spondyloarthropathy 31.4 TNF LTA IL6 IL10
16 arthropathy 31.4 TNF LTA IL6 IL1RN CRP
17 exanthem 31.4 TNFRSF1B TNF IL6 IL1RN IL10 CRP
18 myocarditis 31.3 TNF IL6 IL10 HLA-DQB1
19 idiopathic anterior uveitis 31.3 TNF IL6
20 thyroiditis 31.3 TNF IL6 IL10
21 conjunctivitis 31.3 TNF IL6 IL10
22 disseminated intravascular coagulation 31.3 TNF IL6 IL10 CRP
23 neuritis 31.3 TNF IL6 IL10
24 nasopharyngitis 31.2 TNFRSF1B TNF CRP
25 bone resorption disease 31.2 TNF IL6 CRP BGLAP
26 juvenile ankylosing spondylitis 31.2 TNFRSF1B TNF IL1RN
27 bronchiolitis 31.1 TNF IL6 IL10 CRP
28 lyme disease 31.1 TNF IL6 HLA-DRB1 HLA-DQB1 CRP
29 spondylitis 31.1 TNFRSF1B TNF LTA IL6 IL1RN IL10
30 polyarteritis nodosa 31.1 IL6 HLA-DRB1 CRP
31 osteomyelitis 31.1 TNF IL6 IL1RN IL10
32 arthritis 31.1 TNFRSF1B TNF SLC11A1 LTA IL6 IL1RN
33 chickenpox 31.1 TNFRSF1B TNF IL6 IL10 CRP
34 tenosynovitis 31.1 TNFRSF1B TNF IL6 CRP
35 bronchiolitis obliterans 31.0 TNF IL6 IL10 CRP
36 keratitis, hereditary 31.0 TNF IL6 IL10
37 spondyloarthropathy 1 31.0 TNFRSF1B TNF S100A9 IL1RN IL1R1 CRP
38 eye disease 31.0 TNF IL6 IL1RN IL1R1 IL10 CRP
39 macular retinal edema 31.0 TNFRSF1B TNF IL6
40 fasciitis 31.0 TNF IL6 IL1RN
41 hemophagocytic lymphohistiocytosis 31.0 TNF IL2RA IL10
42 sleep apnea 31.0 TNF IL6 IL10 CRP
43 systemic autoimmune disease 31.0 IL6 CRP
44 rheumatic fever 31.0 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
45 peritonitis 30.9 TNF IL6 IL10 CRP
46 childhood type dermatomyositis 30.9 TNFRSF1B TNF IL6 HLA-DQA1
47 castleman disease 30.9 IL6 IL10 CRP
48 meningitis 30.9 TNF IL6 IL10 CRP
49 chorioretinitis 30.9 TNFRSF1B TNF IL6 IL10
50 purpura 30.9 TNF IL6 IL10 CRP

Graphical network of the top 20 diseases related to Juvenile Rheumatoid Arthritis:



Diseases related to Juvenile Rheumatoid Arthritis

Symptoms & Phenotypes for Juvenile Rheumatoid Arthritis

Human phenotypes related to Juvenile Rheumatoid Arthritis:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001369
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
4 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
5 joint dislocation 58 31 frequent (33%) Frequent (79-30%) HP:0001373
6 joint stiffness 58 31 frequent (33%) Frequent (79-30%) HP:0001387
7 malabsorption 58 31 frequent (33%) Frequent (79-30%) HP:0002024
8 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
9 generalized hyperkeratosis 58 31 frequent (33%) Frequent (79-30%) HP:0005595
10 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
11 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
12 psoriasiform dermatitis 58 31 frequent (33%) Frequent (79-30%) HP:0003765
13 abnormality of the pleura 58 31 frequent (33%) Frequent (79-30%) HP:0002103
14 uveitis 58 31 frequent (33%) Frequent (79-30%) HP:0000554
15 mediastinal lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0100721
16 nail pits 58 31 frequent (33%) Frequent (79-30%) HP:0001803
17 cartilage destruction 58 31 frequent (33%) Frequent (79-30%) HP:0100773
18 abnormality of the sacroiliac joint 58 31 frequent (33%) Frequent (79-30%) HP:0100781
19 abnormal fingernail morphology 31 frequent (33%) HP:0001231
20 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
21 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
22 pericardial effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0001698
23 abnormality of the nail 58 Frequent (79-30%)
24 thickened skin 58 Frequent (79-30%)
25 abnormality of the fingernails 58 Frequent (79-30%)
26 abnormal joint morphology 58 Frequent (79-30%)

UMLS symptoms related to Juvenile Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.1 BGLAP HAPLN1 HLA-DPB1 HLA-DQB1 IL1RN SLC11A1

MGI Mouse Phenotypes related to Juvenile Rheumatoid Arthritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 HAPLN1 HLA-DQA1 HLA-DQB1 IL10 IL1R1 IL1RN
2 homeostasis/metabolism MP:0005376 10.18 CRP DEK HAPLN1 HLA-DQB1 IL10 IL1R1
3 immune system MP:0005387 10.17 CRP HLA-DQA1 HLA-DQB1 IL10 IL1R1 IL1RN
4 cardiovascular system MP:0005385 10.16 CRP HLA-DQB1 IL10 IL1R1 IL1RN IL2RA
5 endocrine/exocrine gland MP:0005379 10.13 HLA-DQA1 HLA-DQB1 IL10 IL1R1 IL2RA IL2RB
6 mortality/aging MP:0010768 10 HAPLN1 HLA-DQB1 IL10 IL1R1 IL1RN IL2RA
7 liver/biliary system MP:0005370 9.86 HLA-DQB1 IL10 IL1R1 IL2RB IL6 LTA
8 neoplasm MP:0002006 9.5 DEK IL10 IL1R1 IL6 SLC11A1 TNF
9 respiratory system MP:0005388 9.23 HLA-DQB1 IL10 IL1R1 IL2RA IL6 LTA

Drugs & Therapeutics for Juvenile Rheumatoid Arthritis

Drugs for Juvenile Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
2
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Famotidine Approved Phase 4 76824-35-6 3325
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8 Liver Extracts Phase 4
9 Proton Pump Inhibitors Phase 4
10 Anti-Ulcer Agents Phase 4
11 Antacids Phase 4
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
13 Histamine H2 Antagonists Phase 4
14 Histamine Antagonists Phase 4
15
Histamine Phosphate Phase 4 51-74-1 65513
16 Pharmaceutical Solutions Phase 4
17 Central Nervous System Depressants Phase 4
18 Anesthetics Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic alpha-2 Receptor Agonists Phase 4
21 Hypnotics and Sedatives Phase 4
22 Anesthetics, General Phase 4
23 Anesthetics, Inhalation Phase 4
24 Adrenergic Agents Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Anti-Infective Agents Phase 4
28 Gastrointestinal Agents Phase 4
29
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
30
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
31
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
32
Infliximab Approved Phase 3 170277-31-3
33
Calcium carbonate Approved, Investigational Phase 3 471-34-1
34
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
35
Hydroxychloroquine Approved Phase 3 118-42-3 3652
36
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
37
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
38
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
39
Tofacitinib Approved, Investigational Phase 3 477600-75-2
40
Ibuprofen Approved Phase 3 15687-27-1 3672
41
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Certolizumab pegol Approved Phase 3 428863-50-7
44
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
45
Sodium citrate Approved, Investigational Phase 3 68-04-2
46
tannic acid Approved Phase 2, Phase 3 1401-55-4
47
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
49
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
50
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
2 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
5 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
6 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
7 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
8 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
9 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
10 A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
11 A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
12 Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02034474 Phase 4 Tocilizumab;Placebo
13 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
14 A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
15 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
16 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
17 An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
18 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
19 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
20 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
21 An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02396212 Phase 3
22 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
23 β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
24 A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
25 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
26 A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Completed NCT00889863 Phase 3 canakinumab;placebo
27 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
28 A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
29 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
30 Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
31 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
32 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics Completed NCT01835470 Phase 3 Abatacept
33 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977) Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
34 A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
35 Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis Completed NCT00570934 Phase 3 Placebo
36 EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS Completed NCT02592434 Phase 3 CP-690,550 (tofacitinib)
37 Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development Completed NCT00420251 Phase 3 Genotropin
38 An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever Completed NCT00891046 Phase 3 Canakinumab
39 Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977) Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
40 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
41 An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA Completed NCT00144664 Phase 3 MRA(Tocilizumab)
42 A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
43 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
44 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
45 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
46 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP Completed NCT00144612 Phase 3 MRA(Tocilizumab)
47 A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3 Infliximab
48 A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
49 A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
50 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone

Search NIH Clinical Center for Juvenile Rheumatoid Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Methotrexate
Methotrexate Sodium
Naproxen
Naproxen sodium
oxaprozin
solufenum
Sulfasalazine
tocilizumab
Tolmetin
Tolmetin Sodium

Genetic Tests for Juvenile Rheumatoid Arthritis

Anatomical Context for Juvenile Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Juvenile Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Juvenile Rheumatoid Arthritis:

40
Bone, T Cells, Testes, Skin, Eye, Liver, Heart

Publications for Juvenile Rheumatoid Arthritis

Articles related to Juvenile Rheumatoid Arthritis:

(show top 50) (show all 8224)
# Title Authors PMID Year
1
Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon. 61 42
31466663 2019
2
The protease systems and their pathogenic role in juvenile idiopathic arthritis. 61 42
31181328 2019
3
MicroRNAs in juvenile idiopathic arthritis: Can we learn more about pathophysiological mechanisms? 61 42
31176874 2019
4
Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. 54 61
19480843 2009
5
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. 54 61
18766426 2009
6
[Immunotherapy using IL-6 receptor as the target]. 54 61
18974624 2008
7
Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis. 54 61
20476957 2008
8
Refractory vertebral sarcoidosis responding to infliximab. 54 61
18766126 2008
9
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. 54 61
18716298 2008
10
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. 54 61
18332104 2008
11
The blockade of IL-6 signaling in rational drug design. 54 61
18473869 2008
12
Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. 54 61
18078633 2007
13
Tuberculous uveitis after treatment with etanercept. 54 61
17364199 2007
14
Construction and purification of the murine p75-murine IgG1 fusion protein. 54 61
17502870 2007
15
Etanercept: a review of its use in the management of rheumatoid arthritis. 54 61
17521223 2007
16
Problems encountered during anti-tumour necrosis factor therapy. 54 61
16979537 2006
17
Etanercept and demyelinating disease in a patient with psoriasis. 54 61
16384777 2006
18
Etanercept for psoriasis in the pediatric population: experience in nine patients. 54 61
16445417 2006
19
Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report. 54 61
16341347 2005
20
Etanercept therapy in children with juvenile rheumatoid arthritis. 54 61
16341346 2005
21
Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 54 61
15801034 2005
22
Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. 54 61
16378499 2005
23
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. 54 61
15468378 2004
24
HLA-DRB1 alleles and HLA-DRB1 shared epitopes are markers for juvenile rheumatoid arthritis subgroups in Colombian mestizos. 54 61
15120191 2004
25
[Polymorphism of human HLA-DRB1 leukocyte antigen alleles and its association to juvenile rheumatoid arthritis in a sample of Colombian mestizo children]. 54 61
14582328 2003
26
Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. 54 61
13130482 2003
27
Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. 54 61
12739045 2003
28
DEK binding to class II MHC Y-box sequences is gene- and allele-specific. 54 61
12823858 2003
29
Anti-TNF therapy for other inflammatory conditions. 54 61
12463467 2002
30
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. 54 61
12022325 2002
31
Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. 54 61
11083287 2000
32
Etanercept (Enbrel): update on therapeutic use. 54 61
11053088 2000
33
Stress induces increases in IL-6 production by leucocytes of patients with the chronic inflammatory disease juvenile rheumatoid arthritis: a putative role for alpha(1)-adrenergic receptors. 54 61
11024553 2000
34
Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. 54 61
10857800 2000
35
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. 54 61
10717011 2000
36
Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. 54 61
10616003 1999
37
Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. 54 61
10505742 1999
38
Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. 54 61
10025933 1999
39
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase. 54 61
10063803 1999
40
Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). 54 61
10065630 1999
41
Autoantibodies to transcriptional regulation proteins DEK and ALY in a patient with systemic lupus erythematosus. 54 61
9952027 1999
42
Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium. 54 61
9506577 1998
43
Cytokines in juvenile rheumatoid arthritis. 54 61
9309198 1997
44
Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis. 54 61
9150089 1997
45
HLA class II genes in Latvian patients with juvenile rheumatoid arthritis. 54 61
9027967 1997
46
Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. 54 61
8982123 1996
47
Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. 54 61
8912504 1996
48
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. 54 61
8843861 1996
49
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. 54 61
7473488 1995
50
Interaction between HLA-DR and HLA-DP, and between HLA and interleukin 1 alpha in juvenile rheumatoid arthritis indicates heterogeneity of pathogenic mechanisms of the disease. 54 61
7558921 1995

Variations for Juvenile Rheumatoid Arthritis

ClinVar genetic disease variations for Juvenile Rheumatoid Arthritis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(8;9)(q13;p22)dnTranslocation Pathogenic 267809

Expression for Juvenile Rheumatoid Arthritis

Search GEO for disease gene expression data for Juvenile Rheumatoid Arthritis.

Pathways for Juvenile Rheumatoid Arthritis

Pathways related to Juvenile Rheumatoid Arthritis according to KEGG:

36
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630

Pathways related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 TNFRSF1B TNF SLC11A1 S100A9 S100A8 LTA
2
Show member pathways
13.85 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
3
Show member pathways
13.71 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
4
Show member pathways
13.57 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
5
Show member pathways
13.44 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
6
Show member pathways
13.31 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
7
Show member pathways
13.24 TNF IL2RB IL2RA IL1R1 HLA-DRB1 HLA-DQB1
8
Show member pathways
13.18 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
9
Show member pathways
12.85 TNF LTA IL6 IL2RA IL10 HLA-DRB1
10 12.83 TNF LTA IL6 HLA-DRB1 HLA-DQB1 HLA-DQA1
11
Show member pathways
12.83 TNF IL6 IL2RB IL2RA HLA-DRB1 HLA-DQB1
12
Show member pathways
12.79 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
13
Show member pathways
12.73 TNFRSF1B TNF LTA IL6 IL1R1
14
Show member pathways
12.67 TNFRSF1B TNF IL2RA IL10 HLA-DRB1 HLA-DQB1
15 12.6 TNFRSF1B TNF IL2RB IL2RA IL1RN IL10
16
Show member pathways
12.4 IL2RB IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
17
Show member pathways
12.39 TNF IL6 IL2RB IL2RA IL1R1 IL10
18
Show member pathways
12.37 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
19
Show member pathways
12.37 IL6 IL2RB IL2RA IL10
20
Show member pathways
12.37 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
21
Show member pathways
12.36 TNF S100A9 S100A8 IL6
22
Show member pathways
12.29 TNF LTA IL6 IL2RA IL10
23
Show member pathways
12.29 TNF IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
24
Show member pathways
12.25 TNF IL6 IL1RN IL1R1
25
Show member pathways
12.24 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
26 12.23 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
27 12.21 TNF IL6 IL1RN IL10
28 12.17 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
29 12.14 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
30
Show member pathways
12.1 TNF LTA IL6 IL1R1 IL10
31 12.04 TNF IL6 IL2RB IL2RA IL10
32 12.02 TNFRSF1B TNF IL6 IL10
33
Show member pathways
12.01 IL2RB IL2RA IL1R1 HLA-DRB1
34 12 TNFRSF1B TNF LTA IL6
35
Show member pathways
11.98 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
36 11.96 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
37 11.95 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
38 11.94 TNF IL6 IL1R1 IL10
39 11.94 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
40 11.92 IL6 IL2RB IL2RA IL10
41 11.92 TNF IL6 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
42
Show member pathways
11.83 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
43 11.78 TNF IL6 IL10
44 11.78 TNF LTA IL2RB IL2RA IL1R1 IL10
45 11.77 TNF IL6 IL10
46 11.76 TNF IL6 IL1RN IL10
47 11.75 HLA-DRB1 HLA-DQB1 HLA-DQA1
48
Show member pathways
11.72 LTA IL2RB IL2RA
49
Show member pathways
11.68 TNF IL2RB IL2RA
50 11.66 TNF LTA IL6 IL2RB IL2RA IL1R1

GO Terms for Juvenile Rheumatoid Arthritis

Cellular components related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.34 TNFRSF1B TNF SLC11A1 S100A9 S100A8 LTA
2 extracellular space GO:0005615 10.16 TNF S100A9 S100A8 LTA IL6 IL1RN
3 extracellular region GO:0005576 10.03 TNFRSF1B TNF S100A9 S100A8 LTA IL6
4 cell surface GO:0009986 10 TNF IL2RB IL2RA IL1R1 HLA-DRB1 HLA-DPB1
5 external side of plasma membrane GO:0009897 9.93 TNF IL2RB IL2RA IL1R1 HLA-DRB1
6 endosome membrane GO:0010008 9.85 SLC11A1 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
7 trans-Golgi network membrane GO:0032588 9.73 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
8 endocytic vesicle membrane GO:0030666 9.71 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
9 ER to Golgi transport vesicle membrane GO:0012507 9.67 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
10 transport vesicle membrane GO:0030658 9.62 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
11 interleukin-2 receptor complex GO:0005893 9.48 IL2RB IL2RA
12 clathrin-coated endocytic vesicle membrane GO:0030669 9.46 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
13 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
14 MHC class II protein complex GO:0042613 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1

Biological processes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.07 S100A9 S100A8 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
2 defense response to bacterium GO:0042742 9.98 TNF SLC11A1 S100A9 S100A8 IL10
3 T cell receptor signaling pathway GO:0050852 9.95 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 TNF S100A9 S100A8 IL6
5 defense response to Gram-positive bacterium GO:0050830 9.88 TNF LTA IL6 CRP
6 cellular response to lipopolysaccharide GO:0071222 9.88 TNFRSF1B TNF IL6 IL1RN IL10
7 positive regulation of T cell proliferation GO:0042102 9.85 IL6 IL2RA HLA-DPB1
8 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.85 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
9 response to lipopolysaccharide GO:0032496 9.85 TNFRSF1B SLC11A1 S100A8 LTA IL10
10 positive regulation of interleukin-6 production GO:0032755 9.84 TNF IL6 IL1RN
11 antimicrobial humoral response GO:0019730 9.84 SLC11A1 S100A9 S100A8
12 regulation of inflammatory response GO:0050727 9.84 TNF S100A9 S100A8 IL1R1
13 humoral immune response GO:0006959 9.83 TNF LTA IL6
14 positive regulation of phagocytosis GO:0050766 9.81 TNF SLC11A1 IL2RB
15 negative regulation of T cell proliferation GO:0042130 9.8 IL2RA IL10 HLA-DRB1
16 interferon-gamma-mediated signaling pathway GO:0060333 9.8 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
17 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL10
18 response to glucocorticoid GO:0051384 9.77 TNF IL6 IL1RN IL10 BGLAP
19 cytokine-mediated signaling pathway GO:0019221 9.76 TNFRSF1B TNF IL6 IL2RB IL2RA IL1RN
20 antigen processing and presentation GO:0019882 9.71 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
21 positive regulation of glial cell proliferation GO:0060252 9.69 TNF LTA IL6
22 interleukin-2-mediated signaling pathway GO:0038110 9.68 IL2RB IL2RA
23 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 IL1RN IL10
24 regulation of neuroinflammatory response GO:0150077 9.68 TNFRSF1B IL6
25 leukocyte migration involved in inflammatory response GO:0002523 9.68 S100A9 S100A8
26 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
28 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.65 HLA-DRB1 HLA-DQB1
29 positive regulation of interferon-gamma production GO:0032729 9.65 TNF SLC11A1 LTA IL1R1 HLA-DPB1
30 inflammatory response GO:0006954 9.65 TNFRSF1B TNF SLC11A1 S100A9 S100A8 IL6
31 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 IL6 IL1RN
32 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.64 TNF LTA
33 sequestering of zinc ion GO:0032119 9.62 S100A9 S100A8
34 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.62 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
35 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.61 HLA-DRB1 HLA-DQB1
36 receptor biosynthetic process GO:0032800 9.61 TNF IL10
37 negative regulation of lipid storage GO:0010888 9.61 TNF IL6 CRP
38 chemokine production GO:0032602 9.6 S100A9 S100A8
39 neutrophil aggregation GO:0070488 9.57 S100A9 S100A8
40 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.56 TNF LTA
41 immune response GO:0006955 9.44 TNFRSF1B TNF SLC11A1 LTA IL6 IL2RA

Molecular functions related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 TNF LTA IL6 IL1RN IL10
2 RAGE receptor binding GO:0050786 9.43 S100A9 S100A8
3 arachidonic acid binding GO:0050544 9.4 S100A9 S100A8
4 Toll-like receptor 4 binding GO:0035662 9.37 S100A9 S100A8
5 interleukin-2 binding GO:0019976 9.32 IL2RB IL2RA
6 interleukin-2 receptor activity GO:0004911 9.26 IL2RB IL2RA
7 MHC class II receptor activity GO:0032395 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1

Sources for Juvenile Rheumatoid Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....